PPAR-γ agonists improve RAI uptake in patients with high tumor PPAR-γ expression [81], while retinoids restore RAI avidity in 40–50% of RAIR cases, though their limited monotherapy efficacy warrants investigation in rational combinations [82]. Here, PPARG is linked to neoplasm.